Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women
保存先:
| 著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | artículo original |
| 出版日付: | 2008 |
| その他の書誌記述: | Ideal methods to monitor HPV neutralizing antibodies induced by vaccination have not been established yet. Here, we evaluated systemic and cervical antibody levels induced by HPV16/18 AS04-adjuvanted vaccine (GlaxoSmithKline Biologicals) using a secreted alkaline phosphatase neutralization assay (SEAPNA) and enzyme-linked immunosorbent assay (ELISA). Serum and cervical secretions from 50 vaccinated women were used to assess (1) overall assay reproducibility; (2) inter-assay and inter-specimen correlation; (3) correlations between month 1 and month 12 titers. Strong correlations between SEAP-NA and ELISA were observed (serum anti-HPV16/18, = 0.91/0.85; cervix anti-HPV16/18, = 0.84/0.89). Systemic and cervical antibody measures also correlated well (range: 0.64–0.75); except at mid-cycle (range: 0.28–0.65). Correlations between antibody levels at 1 and 12 months following the start of vaccination were poor (range: 0.16–0.38). In conclusion, HPV16/18 VLP-based ELISA is a reliable and valid method to monitor anti-HPV16/18 neutralizing potential for the first year following vaccination; however, additional studies will be required to better define the effects of the time on cycle and patterns of antibody response over time following vaccination. © 2008 Elsevier Ltd. All rights reserved. |
| 国: | Kérwá |
| 機関: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| 言語: | Inglés |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/102685 |
| オンライン･アクセス: | https://hdl.handle.net/10669/102685 https://doi.org/10.1016/j.vaccine.2008.04.074 |
| キーワード: | Human papillomavirus Neutralization assay Cervical secretions |